Why is Glaxosmi. Pharma falling/rising?

As of 07-Aug, Glaxosmithkline Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 2,676.00, which reflects a decrease of 35.85 or 1.32%. The stock has been underperforming significantly, having lost 16.24% over the last six days and is trading below all key moving averages. In terms of returns, the stock has seen a 15.35% drop over the past week and an 18.46% decline over the past month, while it has a year-to-date increase of 19.11%. Despite its high management efficiency indicated by a return on equity of 42.32% and a low debt-to-equity ratio, the recent performance suggests negative sentiment among investors.
In the broader market context, the stock's short-term performance is notably worse than the benchmark Sensex, which has only declined by 0.69% over the past week. The significant underperformance of Glaxosmithkline Pharmaceuticals Ltd compared to the benchmark indicates a lack of investor confidence, despite rising participation in trading volumes. The stock's liquidity remains adequate for trading, but the consistent downward trend and poor recent returns suggest that investors are cautious, leading to the current price decline.